Plant Health Care secures Arysta commercialisation deal - UPDATE

Plant Health Care (PHC), the developer of naturally derived agricultural products, has secured a long-awaited commercial contract with agrichemicals giant Arysta LifeScience Corporation.

Plant Health Care (PHC), the developer of naturally derived agricultural products, has secured a long-awaited commercial contract with agrichemicals giant Arysta LifeScience Corporation.

Following on from a research agreement between the two companies, the pair have agreed to develop and commercialise PHC's Harpin '' crop improvement technology in several crops and markets, in combination with a number of private equity-owned Arysta's leaf treatment products.

Advertisement - Article continues below

The companies confirmed that, following official registration, the combined product would be ready for first sales in the USA in time for the 2014 spraying season.

PHC and Arysta's research has demonstrated that use of Harpin in combination with plant protection fungicides called triazoles can make a significant contribution to the management of the increased disease resistance being seen in the popular range of strobilurin fungicides.

Wayne Hewett, President and Chief Executive Officer (CEO) of Arysta LifeScience, said the technology had been "validated in the United States corn and soybean market and Arysta LifeScience is focused on launching new products in the United States market in 2014 as well as developing the concept in a number of crops and countries."

Paul Schmidt, CEO of PHC, added that the deal marked "a significant step forward for Plant Health Care" but did not disclose the commercial terms of the deal.

In March, broker Nomura Code noted that PHC had hoped "to soon conclude the foliar Harpin deal that was mentioned in the January trading update. We expect this deal to be significant with the potential for a circa $1.0m upfront payment which would demonstrate significant value seen in the product by another well known agrichemicals company."

On the announcement of the deal, Nomura's John-Marc Bunce added that "we also see the speed of progress in this relationship to commercial launch as a positive indicator of the buy-in from this global agrichemicals company".

Shares in PHC remained unmoved at 87.50p at 11.09 on the day of the announcement.




Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular


These seven charts show exactly why you must own gold today

Covid-19 is accelerating many trends that were already in existence. The rising gold price is one such trend. These seven charts, says Dominic Frisby,…
3 Jun 2020

Disease, rioting and mass unemployment – so why are markets soaring?

Despite some pretty strong headwinds in the last year, America’s S&P 500 stock index is close to all-time highs. John Stepek explains why markets seem…
4 Jun 2020

This looks like the biggest opportunity in today’s markets

With low interest rates and constant money-printing, most assets have become expensive. But one major asset class hasn’t. John Stepek explains why com…
2 Jun 2020